Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OMGA Stock Forecast 2026-2027
$0.02
Current Price
$110,732
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OMGA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
OMGA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-50.0%
1 Year Change
0.0%
Year-to-Date Change
-98.9%
From 52W High of $1.71
+95.0%
From 52W Low of $0.01
📊 TOP ANALYST CALLS
Did OMGA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Omega Therapeutics is one of their latest high-conviction picks.
Latest OMGA Stock Price Targets & Analyst Predictions
OMGA has shown a year-to-date change of 0.0% and a 1-year change of -50.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for OMGA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OMGA Analyst Ratings
3
Buy
0
Hold
0
Sell
OMGA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.02
Latest OMGA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OMGA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $4.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $12.00 |
| Aug 7, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $6.00 |
| Aug 7, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $12.00 |
| Jun 18, 2024 | Raymond James | Ryan Deschner | Outperform | Initiates | $12.00 |
| May 13, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $12.00 |
| May 7, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $7.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $12.00 |
| Apr 3, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $9.00 |
| Apr 1, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $7.00 |
| Jan 4, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $12.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $12.00 |
| Nov 10, 2023 | Wedbush | Robert Driscoll | Outperform | Maintains | $12.00 |
| Sep 1, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| Aug 4, 2023 | Chardan Capital | Buy | Reiterates | $N/A | |
| Jun 6, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| May 8, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $12.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| Mar 24, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $11.00 |
| Mar 10, 2023 | JonesTrading | Catherine Novack | Buy | Initiates | $11.00 |
Omega Therapeutics, Inc. (OMGA) Competitors
The following stocks are similar to Omega Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Omega Therapeutics, Inc. (OMGA) Financial Data
Valuation Metrics
Market Cap
$110,732
Enterprise Value
$60.10M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+22.4%
Gross Margin
N/A
Operating Margin
-3,240.5%
Net Margin
N/A
EPS Growth
+214.3%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
1.6x
Debt/Equity
11.1x
ROE
-167.9%
ROA
-47.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Omega Therapeutics, Inc. (OMGA) Business Model
About Omega Therapeutics, Inc.
What They Do
Develops innovative epigenomic therapeutics for diseases.
Business Model
Omega Therapeutics focuses on developing epigenomic therapeutics that modulate gene expression to treat genetic disorders, cancers, and other diseases. The company leverages its proprietary platform, Omega Dev, to create personalized medicine solutions, positioning itself within the rapidly growing biotechnology market.
Additional Information
Headquartered in Cambridge, Massachusetts, Omega Therapeutics benefits from its location in a prominent biotech hub, enabling collaborations and access to essential research resources. The company aims to address significant medical needs with its innovative therapies, contributing to advancements in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
93
CEO
Dr. Kaan Certel Ph.D.
Country
United States
IPO Year
2021
Website
omegatherapeutics.comOmega Therapeutics, Inc. (OMGA) Latest News & Analysis
Latest News
Quick Summary
Omega Therapeutics reported a quarterly loss of $0.30 per share, slightly exceeding the expected loss of $0.29, and an improvement from a loss of $0.40 per share a year prior.
Why It Matters
Omega Therapeutics' larger-than-expected quarterly loss signals potential operational challenges, impacting investor confidence and future stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Omega Therapeutics (Nasdaq: OMGA) will present new preclinical data at three scientific meetings, highlighting its development of programmable epigenomic mRNA medicines.
Why It Matters
New preclinical data from Omega Therapeutics could indicate advancements in their mRNA medicines, potentially impacting stock performance and investor confidence in biotech innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Omega Therapeutics published preclinical data on OTX-2002 in Nature Communications, demonstrating its potential to regulate the MYC gene in hepatocellular carcinoma models, indicating advancements in precision mRNA therapies.
Why It Matters
The publication of promising preclinical data for OTX-2002 enhances Omega Therapeutics' credibility and potential for breakthroughs in cancer treatment, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
1 year ago
Quick Summary
Omega Therapeutics has appointed Dr. Jennifer Nelson as Senior VP of Research, enhancing its leadership with her 20+ years of experience in RNA and DNA therapies.
Why It Matters
The appointment of Dr. Jennifer Nelson enhances Omega Therapeutics' leadership in RNA therapies, potentially accelerating innovation and attracting investment interest in their mRNA medicine pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Omega Therapeutics (Nasdaq: OMGA) reported its Q2 2024 financial results and recent advancements in developing programmable epigenomic mRNA medicines.
Why It Matters
Omega Therapeutics' financial results and progress in developing innovative mRNA medicines signal potential growth and market impact, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Omega Therapeutics, Inc. (OMGA) reported a quarterly loss of $0.30 per share, beating the Zacks Consensus Estimate of a $0.36 loss and improving from a $0.54 loss a year prior.
Why It Matters
Omega Therapeutics' smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About OMGA Stock
What is Omega Therapeutics, Inc.'s (OMGA) stock forecast for 2026?
Analyst forecasts for Omega Therapeutics, Inc. (OMGA) are not currently available. The stock is trading at $0.02.
Is OMGA stock a good investment in 2026?
According to current analyst ratings, OMGA has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OMGA stock?
Price predictions from Wall Street analysts for OMGA are not currently available. The stock is trading at $0.02.
What is Omega Therapeutics, Inc.'s business model?
Omega Therapeutics focuses on developing epigenomic therapeutics that modulate gene expression to treat genetic disorders, cancers, and other diseases. The company leverages its proprietary platform, Omega Dev, to create personalized medicine solutions, positioning itself within the rapidly growing biotechnology market.
What is the highest forecasted price for OMGA Omega Therapeutics, Inc.?
Price targets from Wall Street analysts for OMGA are not currently available. The stock is trading at $0.02.
What is the lowest forecasted price for OMGA Omega Therapeutics, Inc.?
Price targets from Wall Street analysts for OMGA are not currently available. The stock is trading at $0.02.
What is the overall OMGA consensus from analysts for Omega Therapeutics, Inc.?
The overall analyst consensus for OMGA is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are OMGA stock price projections?
Stock price projections, including those for Omega Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 7, 2026 12:50 PM UTC